PDCD1 and cancer: Especially immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) and its ligand-1 (PD-L1) have dramatically revolutionized the cancer treatment landscape and represented the cornerstone of immunotherapy [9, 10].